, Toshihiro Hatakeyama1,2,*
, Takashi Sano3
, Koki Nakada4
, Tasuku Matsuyama4
, Takeyuki Kiguchi5,6
, Benjamin W. Berg2
, Tetsuhisa Kitamura7
, Hisao Matsushima1
1Department of Emergency and Critical Care Medicine, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan
2SimTiki Simulation Center, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
3Department of Public Health, Jichi Medical University, Shimotsuke, Japan
4Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
5Department of Preventive Services, School of Public Health, Graduate School of Medicine, Kyoto University, Kyoto, Japan
6Department of Critical Care and Trauma Center, Osaka General Medical Center, Osaka, Japan
7Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
© 2025 The Korean Society of Emergency Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).
Author contributions
Conceptualization: T Kawama, TH, T Kiguchi, BWB, T Kitamura, HM; Data curation: T Kawama; Formal analysis: TH, TS; Funding acquisition: T Kawama, TH; Investigation: TH; Methodology: T Kawama, TH, TS, KN, TM; Project administration: TH; Resources: T Kawama, TH; Software: TH, TS; Supervision: HM; Validation: TH, TS; Visualization: T Kawama, TH; Writing–original draft: T Kawama, TH; Writing–review & editing: all authors. All authors read and approved the final manuscript.
Conflicts of interest
Toshihiro Hatakeyama received an overseas scholarship from Dokkyo Medical University, which had no role in conducting this research. The authors have no other conflicts of interest to declare.
Funding
This study was supported by the Research Incentive Grant from Dokkyo Medical University. Dokkyo Medical University had no role in the design and conduct of the study; the collection, management, analyses, and interpretation of the data; the preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Acknowledgments
The authors thank the contributions of all participating hospitals in the Japanese Association for Acute Medicine–Out-of-Hospital Cardiac Arrest (JAAM-OHCA) Registry (https://www.jaamohca-web.com/list/).
Data availability
Data analyzed in this study were obtained from the Japanese Association for Acute Medicine–Out-of-Hospital Cardiac Arrest (JAAM-OHCA) Registry. The data are not publicly accessible, as they were used under license for this study. However, data are available from the corresponding author upon reasonable request and with permission from JAAM and the hospital to which the author belongs in.
| Characteristic | Total (n=4,413) |
Serum lactate to albumin ratio |
P-value | |||
|---|---|---|---|---|---|---|
| First quartile (≤2.23) (n=1,104) | Second quartile (>2.23 and ≤3.39) (n=1,111) | Third quartile (>3.39 and ≤4.70) (n=1,096) | Fourth quartile (>4.70) (n=1,102) | |||
| Male sex | 2,914 (66.0) | 797 (72.2) | 776 (69.9) | 671 (61.2) | 670 (60.8) | <0.001 |
| Age (yr) | 73 (62–82) | 70 (58–78) | 71 (59–80) | 75 (65–83) | 77 (67–85) | <0.001 |
| Over-the-telephone dispatcher CPR guidance | 2,034 (46.1) | 498 (45.1) | 513 (46.2) | 519 (47.4) | 504 (45.7) | 0.760 |
| Year of occurrence of OHCA | 0.320 | |||||
| 2014 | 263 (6.0) | 70 (6.3) | 71 (6.4) | 66 (6.0) | 56 (5.1) | |
| 2015 | 575 (13.0) | 135 (12.2) | 145 (13.1) | 139 (12.7) | 156 (14.2) | |
| 2016 | 597 (13.5) | 146 (13.2) | 150 (13.5) | 137 (12.5) | 164 (14.9) | |
| 2017 | 635 (14.4) | 151 (13.7) | 182 (16.4) | 158 (14.4) | 144 (13.1) | |
| 2018 | 664 (15.1) | 168 (15.2) | 163 (14.7) | 165 (15.1) | 168 (15.2) | |
| 2019 | 659 (14.9) | 168 (15.2) | 150 (13.5) | 190 (17.3) | 151 (13.7) | |
| 2020 | 514 (11.7) | 131 (11.9) | 129 (11.6) | 132 (12.0) | 122 (11.1) | |
| 2021 | 506 (11.5) | 135 (12.2) | 121 (10.9) | 109 (9.9) | 141 (12.8) | |
| Etiology of the cardiac arrest | <0.001 | |||||
| Cardiac | 3,147 (71.3) | 875 (79.3) | 796 (71.6) | 754 (68.8) | 722 (65.5) | |
| Noncardiac | ||||||
| Respiratory disease | 601 (13.6) | 64 (5.8) | 107 (9.6) | 168 (15.3) | 262 (23.8) | |
| Cerebrovascular disease | 544 (12.3) | 153 (13.9) | 193 (17.4) | 145 (13.2) | 53 (4.8) | |
| Malignant tumor | 121 (2.7) | 12 (1.1) | 15 (1.4) | 29 (2.6) | 65 (5.9) | |
| Prehospital information | ||||||
| Bystander event witness | 2,942 (66.7) | 867 (78.5) | 783 (70.5) | 677 (61.8) | 615 (55.8) | <0.001 |
| Bystander CPR | 2,133 (48.3) | 596 (54.0) | 531 (47.8) | 515 (47.0) | 491 (44.6) | <0.001 |
| First documented on-scene cardiac rhythm | <0.001 | |||||
| Shockable (VF or pVT) | 1,235 (28.0) | 617 (55.9) | 376 (33.8) | 178 (16.2) | 64 (5.8) | |
| Nonshockable (PEA or asystole) | 3,178 (72.0) | 487 (44.1) | 735 (66.2) | 918 (83.8) | 1,038 (94.2) | |
| Prehospital adrenaline | 1,474 (33.4) | 193 (17.5) | 355 (32.0) | 456 (41.6) | 470 (42.7) | <0.001 |
| Prehospital advanced airway management | 2,196 (49.8) | 398 (36.1) | 544 (49.0) | 628 (57.3) | 626 (56.8) | <0.001 |
| Prehospital ROSC | 2,112 (47.9) | 840 (76.1) | 569 (51.2) | 401 (36.6) | 302 (27.4) | <0.001 |
| In-hospital information | ||||||
| Practice time | ||||||
| Time from emergency call to the measurement of laboratory data (min) | 40 (32–49) | 40 (32–50) | 38 (31.5–46) | 40 (33–48) | 41 (34–50) | <0.001 |
| Time from hospital arrival to the measurement of laboratory data (min) (n=4,310)a) | 7 (4–12) | 8 (4–13) | 7 (4–11) | 7 (4–11) | 8 (5–12) | <0.001 |
| Laboratory data | ||||||
| Lactate (mmol/L) | 11.0±5.8 | 5.2±2.4 | 9.6±1.7 | 12.5±2.2 | 16.6±7.3 | <0.001 |
| Albumin (g/dL) | 3.2±0.7 | 3.7±0.6 | 3.4±0.5 | 3.1±0.5 | 2.6±0.6 | <0.001 |
| Critical care (targeted temperature management) | 1,157 (26.2) | 455 (41.2) | 359 (32.3) | 221 (20.2) | 122 (11.1) | <0.001 |
Values are presented as number (%) or median (interquartile range). Percentages may not total 100 due to rounding. Comparison between the four groups was evaluated with analysis of variance or Kruskal-Wallis test for continuous variables and chi-squared test for categorial variables.
OHCA, out-of-hospital cardiac arrest; CPR, cardiopulmonary resuscitation; VF, ventricular fibrillation; pVT, pulseless ventricular tachycardia; PEA, pulseless electrical activity; ROSC, return of spontaneous circulation.
a)First quartile, 1,075 patients; second quartile, 1,091 patients; third quartile, 1,069 patients; and fourth quartile, 1,075 patients.
| Outcome |
Serum lactate to albumin ratio |
P-value for trend | |||
|---|---|---|---|---|---|
| First quartile (≤2.23) (n=1,104) | Second quartile (>2.23 and 3.39) (n=1,111) | Third quartile (>3.39 and 4.70) (n=1,096) | Fourth quartile (>4.70) (n=1,102) | ||
| 30-Day survival with good neurological outcomea) | <0.001 | ||||
| No. of patients (%) | 558 (50.5) | 240 (21.6) | 96 (8.8) | 24 (2.2) | |
| Crude OR (95% CI) | Reference | 0.27 (0.23–0.33) | 0.09 (0.07–0.12) | 0.02 (0.01–0.03) | |
| Adjusted OR (95% CI) | Reference | 0.33 (0.26–0.42) | 0.19 (0.14–0.26) | 0.07 (0.04–0.11) | |
| 30-Day survival | <0.001 | ||||
| No. of patients (%) | 730 (66.1) | 436 (39.2) | 236 (21.5) | 107 (9.7) | |
| Crude OR (95% CI) | Reference | 0.34 (0.28–0.40) | 0.14 (0.12–0.17) | 0.06 (0.04–0.07) | |
| Adjusted OR (95% CI) | Reference | 0.42 (0.34–0.52) | 0.25 (0.20–0.32) | 0.13 (0.10–0.17) | |
ORs and 95% CIs for all patients were adjusted for patients' age, sex, over-the-telephone dispatcher CPR guidance, bystander event witness, bystander CPR, the first documented on-scene cardiac rhythm, prehospital adrenaline, prehospital advanced airway management, the etiology of cardiac arrest, and time from emergency call to the measurement of laboratory data.
OR, odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation.
a)Good neurological outcome was defined as cerebral performance category 1 or 2.
| Outcome |
Serum lactate to albumin ratio |
P-value for trend | |||
|---|---|---|---|---|---|
| First quartile (≤1.56) (n=310) | Second quartile (>1.56–2.24) (n=311) | Third quartile (>2.24–3.12) (n=306) | Fourth quartile (>3.12) (n=308) | ||
| 30-Day survival with good neurological outcomea) | <0.001 | ||||
| No. of patients (%) | 244 (78.7) | 221 (71.4) | 162 (52.9) | 112 (36.4) | |
| Crude OR (95% CI) | Reference | 0.67 (0.47–0.97) | 0.30 (0.21–0.43) | 0.15 (0.11–0.22) | |
| Adjusted OR (95% CI) | Reference | 0.65 (0.43–0.99) | 0.27 (0.18–0.41) | 0.15 (0.10–0.23) | |
| 30-Day survival | <0.001 | ||||
| No. of patients (%) | 284 (91.6) | 266 (85.5) | 226 (73.9) | 176 (57.1) | |
| Crude OR (95% CI) | Reference | 0.54 (0.32–0.90) | 0.26 (0.16–0.41) | 0.12 (0.08–0.19) | |
| Adjusted OR (95% CI) | Reference | 0.53 (0.31–0.90) | 0.25 (0.15–0.41) | 0.13 (0.07–0.21) | |
ORs and 95% CIs for all patients were adjusted for patients' age, sex, over-the-telephone dispatcher CPR guidance, bystander event witness, bystander CPR, prehospital adrenaline, prehospital advanced airway management, the etiology of cardiac arrest, and time from emergency call to the measurement of laboratory data.
OR, odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation.
a)Good neurological outcome was defined as cerebral performance category 1 or 2.
| Outcome |
Serum lactate to albumin ratio |
P-value for trend | |||
|---|---|---|---|---|---|
| First quartile (≤2.76) (n=798) | Second quartile (>2.76 and 3.87) (n=799) | Third quartile (>3.87 and 5.17) (n=788) | Fourth quartile (>5.17) (n=793) | ||
| 30-Day survival with good neurological outcomea) | <0.001 | ||||
| No. of patients (%) | 119 (14.9) | 34 (4.3) | 18 (2.3) | 7 (0.9) | |
| Crude OR (95% CI) | Reference | 0.25 (0.17–0.37) | 0.13 (0.08–0.22) | 0.05 (0.02–0.10) | |
| Adjusted OR (95% CI) | Reference | 0.27 (0.18–0.41) | 0.16 (0.10–0.26) | 0.06 (0.02–0.12) | |
| 30-Day survival | <0.001 | ||||
| No. of patients (%) | 270 (33.8) | 137 (17.2) | 96 (12.2) | 54 (6.8) | |
| Crude OR (95% CI) | Reference | 0.40 (0.32–0.51) | 0.27 (0.21–0.35) | 0.14 (0.10–0.19) | |
| Adjusted OR (95% CI) | Reference | 0.41 (0.32–0.52) | 0.28 (0.21–0.36) | 0.14 (0.10–0.20) | |
ORs and 95% CIs for all patients were adjusted for patients' age, sex, over-the-telephone dispatcher CPR guidance, bystander event witness, bystander CPR, prehospital adrenaline, prehospital advanced airway management, the etiology of cardiac arrest, and time from emergency call to the measurement of laboratory data.
OR, odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation.
a)Good neurological outcome was defined as cerebral performance category 1 or 2.
| Characteristic | Total (n=4,413) | Serum lactate to albumin ratio |
P-value | |||
|---|---|---|---|---|---|---|
| First quartile (≤2.23) (n=1,104) | Second quartile (>2.23 and ≤3.39) (n=1,111) | Third quartile (>3.39 and ≤4.70) (n=1,096) | Fourth quartile (>4.70) (n=1,102) | |||
| Male sex | 2,914 (66.0) | 797 (72.2) | 776 (69.9) | 671 (61.2) | 670 (60.8) | <0.001 |
| Age (yr) | 73 (62–82) | 70 (58–78) | 71 (59–80) | 75 (65–83) | 77 (67–85) | <0.001 |
| Over-the-telephone dispatcher CPR guidance | 2,034 (46.1) | 498 (45.1) | 513 (46.2) | 519 (47.4) | 504 (45.7) | 0.760 |
| Year of occurrence of OHCA | 0.320 | |||||
| 2014 | 263 (6.0) | 70 (6.3) | 71 (6.4) | 66 (6.0) | 56 (5.1) | |
| 2015 | 575 (13.0) | 135 (12.2) | 145 (13.1) | 139 (12.7) | 156 (14.2) | |
| 2016 | 597 (13.5) | 146 (13.2) | 150 (13.5) | 137 (12.5) | 164 (14.9) | |
| 2017 | 635 (14.4) | 151 (13.7) | 182 (16.4) | 158 (14.4) | 144 (13.1) | |
| 2018 | 664 (15.1) | 168 (15.2) | 163 (14.7) | 165 (15.1) | 168 (15.2) | |
| 2019 | 659 (14.9) | 168 (15.2) | 150 (13.5) | 190 (17.3) | 151 (13.7) | |
| 2020 | 514 (11.7) | 131 (11.9) | 129 (11.6) | 132 (12.0) | 122 (11.1) | |
| 2021 | 506 (11.5) | 135 (12.2) | 121 (10.9) | 109 (9.9) | 141 (12.8) | |
| Etiology of the cardiac arrest | <0.001 | |||||
| Cardiac | 3,147 (71.3) | 875 (79.3) | 796 (71.6) | 754 (68.8) | 722 (65.5) | |
| Noncardiac | ||||||
| Respiratory disease | 601 (13.6) | 64 (5.8) | 107 (9.6) | 168 (15.3) | 262 (23.8) | |
| Cerebrovascular disease | 544 (12.3) | 153 (13.9) | 193 (17.4) | 145 (13.2) | 53 (4.8) | |
| Malignant tumor | 121 (2.7) | 12 (1.1) | 15 (1.4) | 29 (2.6) | 65 (5.9) | |
| Prehospital information | ||||||
| Bystander event witness | 2,942 (66.7) | 867 (78.5) | 783 (70.5) | 677 (61.8) | 615 (55.8) | <0.001 |
| Bystander CPR | 2,133 (48.3) | 596 (54.0) | 531 (47.8) | 515 (47.0) | 491 (44.6) | <0.001 |
| First documented on-scene cardiac rhythm | <0.001 | |||||
| Shockable (VF or pVT) | 1,235 (28.0) | 617 (55.9) | 376 (33.8) | 178 (16.2) | 64 (5.8) | |
| Nonshockable (PEA or asystole) | 3,178 (72.0) | 487 (44.1) | 735 (66.2) | 918 (83.8) | 1,038 (94.2) | |
| Prehospital adrenaline | 1,474 (33.4) | 193 (17.5) | 355 (32.0) | 456 (41.6) | 470 (42.7) | <0.001 |
| Prehospital advanced airway management | 2,196 (49.8) | 398 (36.1) | 544 (49.0) | 628 (57.3) | 626 (56.8) | <0.001 |
| Prehospital ROSC | 2,112 (47.9) | 840 (76.1) | 569 (51.2) | 401 (36.6) | 302 (27.4) | <0.001 |
| In-hospital information | ||||||
| Practice time | ||||||
| Time from emergency call to the measurement of laboratory data (min) | 40 (32–49) | 40 (32–50) | 38 (31.5–46) | 40 (33–48) | 41 (34–50) | <0.001 |
| Time from hospital arrival to the measurement of laboratory data (min) (n=4,310)a) | 7 (4–12) | 8 (4–13) | 7 (4–11) | 7 (4–11) | 8 (5–12) | <0.001 |
| Laboratory data | ||||||
| Lactate (mmol/L) | 11.0±5.8 | 5.2±2.4 | 9.6±1.7 | 12.5±2.2 | 16.6±7.3 | <0.001 |
| Albumin (g/dL) | 3.2±0.7 | 3.7±0.6 | 3.4±0.5 | 3.1±0.5 | 2.6±0.6 | <0.001 |
| Critical care (targeted temperature management) | 1,157 (26.2) | 455 (41.2) | 359 (32.3) | 221 (20.2) | 122 (11.1) | <0.001 |
| Outcome | Serum lactate to albumin ratio |
P-value for trend | |||
|---|---|---|---|---|---|
| First quartile (≤2.23) (n=1,104) | Second quartile (>2.23 and 3.39) (n=1,111) | Third quartile (>3.39 and 4.70) (n=1,096) | Fourth quartile (>4.70) (n=1,102) | ||
| 30-Day survival with good neurological outcomea) | <0.001 | ||||
| No. of patients (%) | 558 (50.5) | 240 (21.6) | 96 (8.8) | 24 (2.2) | |
| Crude OR (95% CI) | Reference | 0.27 (0.23–0.33) | 0.09 (0.07–0.12) | 0.02 (0.01–0.03) | |
| Adjusted OR (95% CI) | Reference | 0.33 (0.26–0.42) | 0.19 (0.14–0.26) | 0.07 (0.04–0.11) | |
| 30-Day survival | <0.001 | ||||
| No. of patients (%) | 730 (66.1) | 436 (39.2) | 236 (21.5) | 107 (9.7) | |
| Crude OR (95% CI) | Reference | 0.34 (0.28–0.40) | 0.14 (0.12–0.17) | 0.06 (0.04–0.07) | |
| Adjusted OR (95% CI) | Reference | 0.42 (0.34–0.52) | 0.25 (0.20–0.32) | 0.13 (0.10–0.17) | |
| Outcome | Serum lactate to albumin ratio |
P-value for trend | |||
|---|---|---|---|---|---|
| First quartile (≤1.56) (n=310) | Second quartile (>1.56–2.24) (n=311) | Third quartile (>2.24–3.12) (n=306) | Fourth quartile (>3.12) (n=308) | ||
| 30-Day survival with good neurological outcomea) | <0.001 | ||||
| No. of patients (%) | 244 (78.7) | 221 (71.4) | 162 (52.9) | 112 (36.4) | |
| Crude OR (95% CI) | Reference | 0.67 (0.47–0.97) | 0.30 (0.21–0.43) | 0.15 (0.11–0.22) | |
| Adjusted OR (95% CI) | Reference | 0.65 (0.43–0.99) | 0.27 (0.18–0.41) | 0.15 (0.10–0.23) | |
| 30-Day survival | <0.001 | ||||
| No. of patients (%) | 284 (91.6) | 266 (85.5) | 226 (73.9) | 176 (57.1) | |
| Crude OR (95% CI) | Reference | 0.54 (0.32–0.90) | 0.26 (0.16–0.41) | 0.12 (0.08–0.19) | |
| Adjusted OR (95% CI) | Reference | 0.53 (0.31–0.90) | 0.25 (0.15–0.41) | 0.13 (0.07–0.21) | |
| Outcome | Serum lactate to albumin ratio |
P-value for trend | |||
|---|---|---|---|---|---|
| First quartile (≤2.76) (n=798) | Second quartile (>2.76 and 3.87) (n=799) | Third quartile (>3.87 and 5.17) (n=788) | Fourth quartile (>5.17) (n=793) | ||
| 30-Day survival with good neurological outcomea) | <0.001 | ||||
| No. of patients (%) | 119 (14.9) | 34 (4.3) | 18 (2.3) | 7 (0.9) | |
| Crude OR (95% CI) | Reference | 0.25 (0.17–0.37) | 0.13 (0.08–0.22) | 0.05 (0.02–0.10) | |
| Adjusted OR (95% CI) | Reference | 0.27 (0.18–0.41) | 0.16 (0.10–0.26) | 0.06 (0.02–0.12) | |
| 30-Day survival | <0.001 | ||||
| No. of patients (%) | 270 (33.8) | 137 (17.2) | 96 (12.2) | 54 (6.8) | |
| Crude OR (95% CI) | Reference | 0.40 (0.32–0.51) | 0.27 (0.21–0.35) | 0.14 (0.10–0.19) | |
| Adjusted OR (95% CI) | Reference | 0.41 (0.32–0.52) | 0.28 (0.21–0.36) | 0.14 (0.10–0.20) | |
Values are presented as number (%) or median (interquartile range). Percentages may not total 100 due to rounding. Comparison between the four groups was evaluated with analysis of variance or Kruskal-Wallis test for continuous variables and chi-squared test for categorial variables.
OHCA, out-of-hospital cardiac arrest; CPR, cardiopulmonary resuscitation; VF, ventricular fibrillation; pVT, pulseless ventricular tachycardia; PEA, pulseless electrical activity; ROSC, return of spontaneous circulation.
First quartile, 1,075 patients; second quartile, 1,091 patients; third quartile, 1,069 patients; and fourth quartile, 1,075 patients.
ORs and 95% CIs for all patients were adjusted for patients' age, sex, over-the-telephone dispatcher CPR guidance, bystander event witness, bystander CPR, the first documented on-scene cardiac rhythm, prehospital adrenaline, prehospital advanced airway management, the etiology of cardiac arrest, and time from emergency call to the measurement of laboratory data.
OR, odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation.
Good neurological outcome was defined as cerebral performance category 1 or 2.
ORs and 95% CIs for all patients were adjusted for patients' age, sex, over-the-telephone dispatcher CPR guidance, bystander event witness, bystander CPR, prehospital adrenaline, prehospital advanced airway management, the etiology of cardiac arrest, and time from emergency call to the measurement of laboratory data.
OR, odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation.
Good neurological outcome was defined as cerebral performance category 1 or 2.
ORs and 95% CIs for all patients were adjusted for patients' age, sex, over-the-telephone dispatcher CPR guidance, bystander event witness, bystander CPR, prehospital adrenaline, prehospital advanced airway management, the etiology of cardiac arrest, and time from emergency call to the measurement of laboratory data.
OR, odds ratio; CI, confidence interval; CPR, cardiopulmonary resuscitation.
Good neurological outcome was defined as cerebral performance category 1 or 2.